Sun Pharma's lead molecule enters Phase II in the US

Sun Pharmaceutical Industries Ltd on October 20, 2006 has announced that its lead anti-allergic molecule has received permission from the USFDA to enter Phase II trials in the US. This phase II trial is being conducted in the US directly by the Company, using a reputed CR0. This is, so far, the first IND filing and phase II study in the US for an Indian Company working independently without a partner.

Based on pre-clinical and Phase I studies, the product appears to have a safer pharmacologic profile, with faster onset of action without major side effects.

Dilip Shanghvi, the Chairman and Managing Director of the Company said, "We are excited about this NCE candidate, our first-ever lead in Phase II. In our estimate, the Phase II trials should be completed on our own strength, technical as well as financial."

The Company conducts drug discovery research in facilities at Baroda and Mumbai, India. This is the first lead molecule in human trials from the Company’s innovative research program. The Company has shared plans to demerge its innovative R&D programs into a new Company by this fiscal, and expects to share more information about the Innovative pipeline a month prior to listing the new Company.

Source : Equity Bulls

Keywords